4576 Stock Overview
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
D. Western Therapeutics Institute, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥104.00 |
| 52 Week High | JP¥238.00 |
| 52 Week Low | JP¥100.00 |
| Beta | 0.73 |
| 1 Month Change | -16.80% |
| 3 Month Change | -28.28% |
| 1 Year Change | -48.77% |
| 3 Year Change | -64.26% |
| 5 Year Change | -79.24% |
| Change since IPO | -73.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4576 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -7.1% | 1.2% | -1.0% |
| 1Y | -48.8% | -26.2% | 27.9% |
Return vs Industry: 4576 underperformed the JP Biotechs industry which returned -26.2% over the past year.
Return vs Market: 4576 underperformed the JP Market which returned 27.9% over the past year.
Price Volatility
| 4576 volatility | |
|---|---|
| 4576 Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4576's share price has been volatile over the past 3 months.
Volatility Over Time: 4576's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 21 | Yuichi Hidaka | www.dwti.co.jp |
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension.
D. Western Therapeutics Institute, Inc. Fundamentals Summary
| 4576 fundamental statistics | |
|---|---|
| Market cap | JP¥3.34b |
| Earnings (TTM) | -JP¥812.00m |
| Revenue (TTM) | JP¥428.00m |
7.8x
P/S Ratio-4.1x
P/E RatioIs 4576 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4576 income statement (TTM) | |
|---|---|
| Revenue | JP¥428.00m |
| Cost of Revenue | JP¥36.00m |
| Gross Profit | JP¥392.00m |
| Other Expenses | JP¥1.20b |
| Earnings | -JP¥812.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 13, 2024
| Earnings per share (EPS) | -25.27 |
| Gross Margin | 91.59% |
| Net Profit Margin | -189.72% |
| Debt/Equity Ratio | 69.1% |
How did 4576 perform over the long term?
See historical performance and comparison